Ernexa Therapeutics Inc. Warrants
NASDAQ: ERNAW0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Financial Services
- Industry
- Asset Management
- CEO
- Sanjeev Luther
- Employees
- 6
- Headquarters
- Cambridge, United States
- IPO year
- 2024
- Market cap
- $550.5K
- Website
- https://www.ernexatx.com
Loading ERNAW…
Loading profile data…Frequently asked questions about ERNAW
What does Ernexa Therapeutics Inc. Warrants (ERNAW) do?
Operating in the preclinical phase, Ernexa Therapeutics Inc. is dedicated to advancing therapies based on induced mesenchymal stem cells (iMSC) to combat both solid tumors and autoimmune conditions. Its primary therapeutic, ERNA-101, is an allogeneic iMSC specifically formulated to secrete pro-inflammatory cytokines like IL-7 and IL-15 for the t...
Where does ERNAW trade?
Ernexa Therapeutics Inc. Warrants (ERNAW) trades on the NASDAQ Global Market.
What sector is ERNAW in?
Ernexa Therapeutics Inc. Warrants (ERNAW) operates in the Financial Services sector, specifically in the Asset Management industry.
Who is the CEO of Ernexa Therapeutics Inc. Warrants?
Sanjeev Luther is the chief executive officer of Ernexa Therapeutics Inc. Warrants (ERNAW).
Where is Ernexa Therapeutics Inc. Warrants headquartered?
Ernexa Therapeutics Inc. Warrants is headquartered in United States.
Does ERNAW pay a dividend?
Ernexa Therapeutics Inc. Warrants (ERNAW) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did ERNAW go public?
Ernexa Therapeutics Inc. Warrants (ERNAW) completed its initial public offering in 2024.